1-methyl-N⁶-<3-<3-<(dimethylamino)methyl>phenoxy>propyl>-1H-1,2,4-triazole-3,5-diamine | 73278-22-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-N⁶-<3-<3-<(dimethylamino)methyl>phenoxy>propyl>-1H-1,2,4-triazole-3,5-diamine
• 英文别名: N⁵-{3-[3-(dimethylamino-methyl)-phenoxy]-propyl}-1-methyl-1H-[1,2,4]triazole-3,5-diamine；1-methyl-N5-[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-1H-1,2,4-triazole-3,5-diamine；1-Methyl-N⁵-<3-<3-<(dimethylamino)-methyl>-phenoxy>-propyl>-1H-1,2,4-triazol-3,5-diamin；5-N-[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-1-methyl-1,2,4-triazole-3,5-diamine
• CAS: 73278-22-5
• 化学式: C₁₅H₂₄N₆O
• 分子量: 304.395
• InChiKey: AKTRCHWJHNMYTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  81.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-methyl-N⁶-<3-<3-<(dimethylamino)methyl>phenoxy>propyl>-1H-1,2,4-triazole-3,5-diamine 在 苯甲醛 作用下， 以 甲醇 、 苯 为溶剂， 生成 1-methyl-N3-phenylmethylene-N5-[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-1H-1,2,4-triazole-3,5-diamine
  参考文献：
  名称：

  1,2,4-Triazole-3,5-diamine derivatives

  摘要：

  该发明涉及式(I)的化合物及其生理上可接受的盐、水合物和生物前体，其中R.sub.1和R.sub.2代表氢、脂肪族或环脂族基团，或者R.sub.1和R.sub.2与氮原子一起形成5到10元杂环环：Alk代表直链或支链烷基链；Q代表噻吩或苯环，其嵌入到分子的其余部分中；X代表--CH.sub.2 --，--O--或--S--，其中R.sub.6代表氢或甲基；n代表零、1或2；m代表2、3或4；R.sub.3代表氢、取代或未取代的脂肪族或芳基团；R.sub.4和R.sub.5，可以相同也可以不同，每个代表氢、取代或未取代的脂肪族、芳基，或者与氮原子一起形成杂环基团。

  公开号：

  US04318913A1
• 作为产物：
  描述：

  3-(3-aminopropoxy)-N,N-dimethylbenzenemethanamine 以 乙醚 为溶剂， 反应 3.0h， 生成 1-methyl-N⁶-<3-<3-<(dimethylamino)methyl>phenoxy>propyl>-1H-1,2,4-triazole-3,5-diamine
  参考文献：
  名称：

  氰基亚氨基碳酸二苯酯和二氯二苯氧基甲烷作为合成子，用于构建具有医学意义的杂环系统

  摘要：

  描述了由标题化合物制备具有抗组胺（H2）活性的杂环N-氰基胍（包括抗溃疡药西咪替丁），取代的三唑，苯并咪唑和恶二唑的简单高产率方法。

  DOI：

  10.1002/jhet.5570240153

文献信息

• Triazole acylamines, pharmaceutical compositions thereof and method of
  申请人：Glaxo Group Limited

  公开号：US04323566A1

  公开（公告）日：1982-04-06

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2, which may be the same of different, each represent hydrogen, C.sub.1 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, or alkyl substituted by hydroxy, alkoxy, amino alkylamino dialkylamino or cycloalkyl or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom which is oxygen or sulphur; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms, Q represents a furan or thiophene ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5- positions, the furan ring optionally bearing a further substituent R.sub.6 adjacent to the group R.sub.1 R.sub.2 N-Alk, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions; R.sub.6 represents halogen or C.sub.1-4 alkyl which may be substituted by hydroxy or C.sub.1-4 alkoxy; x represents --CH.sub.2 --, --O--, --S--or ##STR2## where R.sub.5 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl with at least two carbon atoms, alkoxyalkyl, or aryl, and R.sub.4 represents hydrogen, alkyl, alkenyl or aralkyl and R.sub.7 represents the group COR.sub.8 where R.sub.8 represents hydrogen, alkyl, aryl, aralkyl, alkoxy, heteroaryl or monocyclic heteroarylalkyl or R.sub.7 represents the group SO.sub.2 R.sub.9 where R.sub.9 represents alkyl or aryl, or R.sub.7 represents the group ##STR3## where Y is oxygen or sulphur and R.sub.10 represents hydrogen, alkyl, cycloalkyl, aryl or aralkyl. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 - antagonists.

  该发明涉及一般式（I）的化合物及其生理上可接受的盐、水合物和生物前体，其中R.sub.1和R.sub.2，它们可以相同也可以不同，分别代表氢、C.sub.1烷基、环烷基、烯基、炔基、芳基烷基、三氟甲基或被羟基、烷氧基、氨基烷基氨基双烷基氨基或环烷基取代的烷基，或R.sub.1和R.sub.2可以与它们连接的氮原子一起形成一个5至10环，该环可能是饱和的或含有至少一个双键，可能未取代或可被一个或多个C.sub.1-3烷基或一个羟基取代和/或可能含有另一个杂原子，该原子是氧或硫；Alk代表1至6个碳原子的直链或支链烷基链，Q代表呋喃或噻吩环，其与分子其余部分的连接是通过2-和5-位置的键，呋喃环可选地带有与基团R.sub.1 R.sub.2 N-Alk相邻的进一步取代基R.sub.6，或Q代表苯环，其与分子其余部分的连接是通过1-和3-或1-和4-位置的键；R.sub.6代表卤素或C.sub.1-4烷基，该烷基可被羟基或C.sub.1-4烷氧基取代；x代表--CH.sub.2--、--O--、--S--或##STR2##其中R.sub.5代表氢或甲基；n代表零、1或2；m代表2、3或4；R.sub.3代表氢、烷基、烯基、芳基烷基、至少有两个碳原子的羟基烷基、烷氧基烷基或芳基，R.sub.4代表氢、烷基、烯基或芳基，R.sub.7代表基团COR.sub.8，其中R.sub.8代表氢、烷基、芳基、芳基烷基、烷氧基、杂芳基或单环杂芳基烷基，或R.sub.7代表基团SO.sub.2R.sub.9，其中R.sub.9代表烷基或芳基，或R.sub.7代表基团##STR3##其中Y为氧或硫，R.sub.10代表氢、烷基、环烷基、芳基或芳基烷基。该化合物的式（I）显示出作为选择性组胺H.sub.2-拮抗剂的药理活性。
• 1H-1,2,4-Triazole-3,5-diamine derivatives and use as selective histamine
  申请人：Glaxo Group Limited

  公开号：US04442110A1

  公开（公告）日：1984-04-10

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R.sub.7 adjacent to the group R.sub.1 R.sub.2 N-Alk-, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions; R.sub.7 represents halogen or C.sub.1-4 alkyl which may be substituted by hydroxy or C.sub.1-4 alkoxy; X represents --CH.sub.2 --, ##STR2## --O-- or --S-- where R.sub.6 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl having at least two carbon atoms, alkoxyalkyl or aryl; and R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, alkyl, alkyl substituted by hydroxy or C.sub.1-3 alkoxy, alkenyl, aralkyl or heteroaralkyl or R.sub.4 and R.sub.5 may together with the nitrogen atom to which they are attached form a 5 to 7-membered saturated heterocyclic ring which may contain another heteroatom, or the group ##STR3## or R.sub.4 and R.sub.5 taken together may represent the group .dbd.CR.sub.8 R.sub.9 where R.sub.8 represents aryl or heteroaryl and R.sub.9 represents hydrogen or alkyl. Preferably when X represents an oxygen atom or ##STR4## and n is zero, then Q only represents a benzene ring. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

  本发明涉及通式（I）的化合物，以及其生理上可接受的盐、水合物和生物前体，其中R.sub.1和R.sub.2，可以相同也可以不同，分别代表氢、C.sub.1-10烷基、环烷基、烯基、炔基、芳基烷基、三氟甲基或被羟基、烷氧基、氨基、烷基氨基、二烷基氨基或环烷基取代的烷基，或R.sub.1和R.sub.2可以与它们附着的氮原子一起形成一个5到10个成员的脂环杂环，该脂环杂环可以饱和或可以含有至少一个双键，可以是未取代的或可以被一个或多个C.sub.1-3烷基基团或羟基基团取代，也可以包含另一个杂原子；Alk代表1到6个碳原子的直链或支链烷基链；Q代表呋喃或噻吩环，其中结合到分子的其余部分是通过2-和5-位置的键，呋喃环可以选择地带有R.sub.1 R.sub.2 N-Alk-基团相邻的另一个取代基R.sub.7，或Q代表苯环，其中结合到分子的其余部分是通过1-和3-或1-和4-位置的键；R.sub.7代表卤素或C.sub.1-4烷基，可以被羟基或C.sub.1-4烷氧基取代；X代表--CH.sub.2 --、##STR2## --O--或--S--，其中R.sub.6代表氢或甲基；n代表零、1或2；m代表2、3或4；R.sub.3代表氢、烷基、烯基、芳基烷基、至少有两个碳原子的羟基烷基、烷氧基烷基或芳基；R.sub.4和R.sub.5，可以相同也可以不同，分别代表氢、烷基、被羟基或C.sub.1-3烷氧基取代的烷基、烯基、芳基烷基或杂芳基烷基，或R.sub.4和R.sub.5可以与它们附着的氮原子一起形成一个5到7个成员的饱和杂环，该杂环可以包含另一个杂原子，或者是基团##STR3##或R.sub.4和R.sub.5一起代表.dbd.CR.sub.8 R.sub.9基团，其中R.sub.8代表芳基或杂芳基，R.sub.9代表氢或烷基。当X代表氧原子或##STR4##且n为零时，最好Q仅代表苯环。公式（I）的化合物表现出选择性组胺H.sub.2-拮抗剂的药理活性。
• 3-[3-[1-piperidinylmethyl]phenoxy]propanamine
  申请人：Glaxo Group Limited

  公开号：US04764612A1

  公开（公告）日：1988-08-16

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the variables are as defined in the specification. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists. Also disclosed are intermediates in the preparation of the compounds of the formula (I).

  本发明涉及通式（I）的化合物及其生理上可接受的盐、水合物和生物前体，其中变量如规范中所定义。式（I）化合物显示出作为选择性组胺H.sub.2 -拮抗剂的药理活性。本发明还揭示了制备式（I）化合物的中间体。
• Triazoleamine derivatives having histamine H.sub.2 -antagonist properties
  申请人：Glaxo Group Limited

  公开号：US04536508A1

  公开（公告）日：1985-08-20

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, which show pharmacological activity as selective histamine H.sub.2 -antagonists.

  本发明涉及通式（I）的化合物及其生理学上可接受的盐，水合物和生物前体，这些化合物具有作为选择性组胺H.sub.2-拮抗剂的药理活性。
• 1,2,4-Triazole derivatives, processes for their production and pharmaceutical compositions containing them
  申请人：GLAXO GROUP LIMITED

  公开号：EP0016565A1

  公开（公告）日：1980-10-01

  The invention relates to compounds of the general formula (I) and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R1 and R2, which may be the same of different, each represent hydrogen, C1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, or alkyl substituted by hydroxy, alkoxy, amino, alkylamino dialkylamino or cycloalkyl or R, and R2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom which is oxygen or sulphur; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms, Q represents a furan or thiophene ring in which incorporation into the rest of the molecule is through bonds at the 2-and 5- positions, the furan ring optionally bearing a further substituent R6 adjacent to the group R 1R2N-Alk, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1 - and 3- or 1 - and 4. positions; R4 represents halogen or C1-4 alkyl which may be substi. tuted by hydroxy or C1-4 alkoxy; X represents -CH2-, -0-, -S- or where R5 represents hydrogen or methyl; n represents zero, 1 or 2; M represents 2, 3 or 4; R represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl with at least two carbon atoms, alkoxyalkyl, or aryl, and R4 represents hydrogen, alkyl, alkenyl, aryl, aralkyl, hydroxyalkyl, acyloxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkyloxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxy, alkoxy, alkylthio or halogen or the group NR7R8 where R7 represents hydrogen, alkyl, alkenyl or aralkyl or R6 represents the group COR9 where R9 represents hydrogen, alkyl, aryl, aralkyl, alkoxy, heteroaryl or monocyclic heteroarylalkyl or R4 represents the group SO2R10 where R10 represents alkyl or aryl, or R8 represents the group where Y is oxygen or sulphur and R 11 represents hydrogen, alkyl, cycloalkyl, aryl or aralkyl. The compounds of formula (I) show pharmacological activity as selective histamine H2- antagonists.

  本发明涉及通式 (I) 的化合物 及其生理上可接受的盐、水合物和生物前体，其中 R1和R2（可以相同或不同）分别代表氢、C1-10烷基、环烷基、烯基、炔基、芳烷基、三氟烷基或被羟基、烷氧基、氨基、烷基氨基二烷基氨基或环烷基取代的烷基或 R、和 R2 可与它们所连接的氮原子一起形成一个 5 至 10 个成员的环，该环可以是饱和的，也可以含有至少一个双键，可以是未取代的，也可以是被一个或多个 C1-3 烷基或羟基取代的，和/或可以含有另一个氧或硫的杂原子； 烷基代表 1-6 个碳原子的直链或支链亚烷基、 Q 代表呋喃或噻吩环，通过 2-位和 5-位上的键与分子的其余部分结合，呋喃环可选择带有与基团 R 1R2N-Alk 相邻的另一个取代基 R6，或 Q 代表苯环，通过 1-位和 3-位或 1-位和 4-位上的键与分子的其余部分结合； R4 代表卤素或可被羟基或 C1-4 烷氧基取代的 C1-4 烷基； X 代表-CH2-、-0-、-S- 或-CH2-。 其中 R5 代表氢或甲基； n 代表零、1 或 2； M 代表 2、3 或 4； R 代表氢、烷基、烯基、芳基、至少含有两个碳原子的羟烷基、烷氧基烷基或芳基，以及 R4 代表氢、烷基、烯基、芳基、芳烷基、羟基烷基、酰氧基烷基、烷氧基烷基、芳氧基烷基、芳基氧基烷基、氨基烷基、烷基氨基烷基、二烷基氨基烷基、羟基、烷氧基、烷硫基或卤素或基团 NR7R8，其中 R7 代表氢、烷基、烯基或芳烷基或 R6 代表基团 COR9（其中 R9 代表氢、烷基、芳基、芳烷基、烷氧基、杂芳基或单环杂 芳烷基），或 R4 代表基团 SO2R10（其中 R10 代表烷基或芳基），或 R8 代表基团 NR7R8（其中 R7 代表氢、烷基、烯基或芳烷基）。 其中 Y 是氧或硫，R 11 代表氢、烷基、环烷基、芳基或芳烷基。 式（I）化合物具有选择性组胺 H2- 拮抗剂的药理活性。